Completion of Clinical Trial - a Significant Achievement for Medicortex Finland
Medicortex Finland Oy ( http://www.medicortex.fi ), a biotechnology company developing a diagnostic kit for brain injury detection based on a medical breakthrough biomarker, completed collection of samples in its second large clinical study. The trial recruited patients who came to the hospital due to a head injury or orthopedic injury and compared them to healthy volunteers.
"Collecting the human samples in this large clinical trial is a significant achievement for Medicortex, and represents an important step forward in the development of the ProbTBITM, a diagnostic kit for head injury" said Dr. Adrian Harel, Chief Executive Officer of Medicortex Finland. "Brain injury is a devastating condition leading to medical complications if not diagnosed. We have the opportunity to develop a portable non-invasive kit for quick detection of mild traumatic brain injury and concussion, and to help patients and families that so desperately need it “
In the clinical trial Medicortex collected body fluid samples from total of 68 subjects, consisting of patients with head injury, patients with orthopedic injury, and healthy volunteers. Two main Finnish hospitals, Turku University hospital and Satakunta Central Hospital in Pori, served as study sites recruiting the patients and collecting the samples. The next step is analyzing the samples for the presence of the novel biomarker and to demonstrate statistical difference between the patients and healthy control subjects. “The biomarker we are targeting has never before been used for mild brain injury detection. The fact that we can readily find it in easily accessible body fluids such as urine and saliva enable us to develop a user-friendly diagnostic kit for concussion and mild TBI detection”, says Dr. Harel.
Dr. Marten Kvist, Medical Director of Medicortex, says "We are excited of the clinical step which will confirm the diagnostic feasibility of the unique biomarker, it will be further developed into a diagnostic aid for first responders and paramedics, it will help prioritize evacuation and reframe from administration of contraindicated medications."
Medicortex is working towards the validation of a Traumatic Brain Injury (TBI) biomarker and incorporating it into a quick and reliable diagnostic kit (ProbTBITM) that can be easily used by the first responders and healthcare professionals.
Medicortex is currently raising money for the next step of clinical development and kit development. Everyone can help to develop the new diagnostic kit by investing.
Medicortex Finland Oy (http://www.medicortex.fi) is a biotechnology company dedicated to improving the diagnostics and treatment of Traumatic Brain Injury (TBI). Its current focus is to develop biomarker diagnostics that evaluate the extent and severity of TBI. Once the company completes the biomarker development its next goal will be to develop an innovative drug to halt the progression of brain injury.
Key words: NFL, ice-hockey, rugby, brain injury, head injury, concussion, diagnostics, TBI, sport, professional athletes, boxing, early detection, military, army, navy, soldier, combat, veteran, trauma, PTSD, clinical trial
This press release contains statements that are "forward-looking statements" that are based upon management's current expectations and assumptions and are subject to a number of risks, uncertainties and other factors that could cause actual results and events to differ materially and adversely from those indicated herein.
Om Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
Concierge Auctions and Engel & Völkers to Sell $29.9 Million New Jersey Estate Without Reserve20.5.2019 17:32:00 CEST | Pressemelding
A 32,507-square-foot Saddle River residence will sell at auction next month via leading global firm Concierge Auctions. Known as “Stone Palace on the Hill,” the home features a glass elevator, tennis court, racquetball court, wine cellar, and two swimming pools. 144 East Saddle River Road was previously listed for $29.9 million and will sell Without Reserve in cooperation with Alina Pogorelova and Lisa Troyano-Ascolese of Engel & Völkers. Bidding, which will be held via Concierge Auctions’ online marketplace, will open on June 21st and close on June 27. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190520005686/en/ 144 East Saddle River Road | New York Metro, NJ (Photo: Business Wire) “The quality of work and detail that went into building this home is perhaps the most impressive element of the property,” said Troyano-Ascolese. “With astounding details from custom gold-plated and forged-iron railings to a complete hand-cut
CNIM to Optimize Renewable Heat Production for Nantes District Heating20.5.2019 17:20:00 CEST | Pressemelding
CNIM, a French international industrial equipment manufacturer and integrator, has entered into an agreement concerning the energy efficiency optimisation at the waste-to-energy plant serving the cities of Nantes and Saint Nazaire, in the North West of France. Under the terms of this agreement, CNIM will install an absorption heat pump to boost the supply of hot water to Nantes. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190520005678/en/ Heat-Pump_13MW_Brive (c) CNIM The delivery is scheduled for October 2019. The new system has been designed to inject 3.1 MW of heat energy into Nantes' district heating system. 2018: Two contracts to upgrade heat networks in France and Switzerland Prior to this agreement, CNIM won two other major contracts to upgrade the energy efficiency of waste-to-energy plants in France and Switzerland, and to supply district heating networks with renewable energy. Supplying 30 MW to Basel's district
MyHeritage utvides til Helse; Lanserer ny DNA-test som tilbyr omfattende og personlig helseinnsikt for forbrukere20.5.2019 17:15:00 CEST | Pressemelding
MyHeritage, den ledende globale tjenesten for familiehistorie og DNA-testing, kunngjorde i dag en stor utvidelse av DNA-produktlinjen med lanseringen av MyHeritage DNA Helse+Aner-testen. Testen gir en ny dimensjon av genetisk innsikt med omfattende helserapporter som kan styrke fremtidige helse- og livsstilsvalg. Det er en utvidelse av den nåværende MyHeritage DNA-testen, og inkluderer sine søylefunksjoner: en prosentvis nedbryting av etnisk opprinnelse og samsvar med slektninger gjennom delt DNA. MyHeritage er nå det eneste globale DNA-selskapet for forbrukere som tilbyr et omfattende helse- og aneprodukt på over 40 språk. Denne pressemeldingen inneholder multimedia. Se hele pressemeldingen her: https://www.businesswire.com/news/home/20190520005670/no/ MyHeritage utvides til Helse; Lanserer ny DNA-test som tilbyr omfattende og personlig helseinnsikt for forbrukere (Graphic: Business Wire) Lanseringen av Helse+Aner-produktet skiller MyHeritage som den eneste hovedtjenesten som forbinde
Phase III study showed nintedanib slows the loss of pulmonary function in people living with systemic sclerosis associated ILD120.5.2019 16:46:00 CEST | Pressemelding
Boehringer Ingelheim today announced that the SENSCIS® trial met its primary endpoint: reduction in the annual rate of decline in forced vital capacity (FVCa) in patients with systemic sclerosis associated interstitial lung disease (SSc-ILD). Results show that nintedanib slows the loss of pulmonary function in patients with SSc-ILD compared to placebo. Patients taking nintedanib showed a 44% reduction in the rate of decline of their lung function, measured in FVC assessed over 52 weeks1. These new data were today published in the New England Journal of Medicine (NEJM) and presented to the medical community at the American Thoracic Society (ATS) International Conference, in Dallas, USA. SENSCIS® is the largest randomised controlled trial to be conducted in patients with SSc-ILD, a disease for which there are currently no approved treatments.1,3,4 Results also showed that nintedanib had a safety and tolerability profile similar to that observed in patients with idiopathic pulmonary fibro
Airship Bolsters its Senior Leadership Team for Accelerated Global Growth20.5.2019 13:00:00 CEST | Pressemelding
Customer engagement company Airship today announced four senior leadership appointments including Dale Flores as vice president of sales Americas, Neil Gariepy as vice president of infrastructure and security, David King Harris as vice president of sales EMEA, and Jeff Winsor as vice president of technology services. Dale Flores will lead the rapid expansion of Airship’s Americas sales organization, growing solution adoption to generate greater business value for customers throughout the region. Flores brings two decades of global SaaS sales and customer success management experience to Airship, including over 14 years leading sales teams at Silverpop and IBM. Most recently, Flores was head of customer success at digital customer experience company Clicktale. Neil Gariepy will lead Airship’s customer engineering, infrastructure and security teams, with responsibility for expanding Airship’s infrastructure globally while further optimizing its cost, performance and security. Gariepy bri
Analogix Introduces Its VirtualLink™ Reference Design for High-Performance Gaming Notebooks20.5.2019 13:00:00 CEST | Pressemelding
Analogix Semiconductor, Inc. today announced the availability of its VirtualLink™ Reference Design which enables VirtualLink directly on the motherboard of high-performance gaming notebooks, allowing them to support virtual reality (VR) over the USB-C™ connector. External accessories can also leverage the reference design to interface legacy graphics processing units (GPUs) to future VirtualLink-enabled VR head-mounted displays. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190520005132/en/ Analogix VirtualLink™ Reference Design brings VR support over the USB-C™ connector to high-performance gaming laptops. (Graphic: Business Wire) Introduced by a consortium led by NVIDIA, Oculus, Valve, AMD, and Microsoft, the VirtualLink Alternate Mode of USB Type-C™ was designed to deliver the power, display, and data required to power VR headsets through a single USB Type-C connector, eliminating the need for multiple cables. It expands